Understand the source comparison
ARA-290 Animal vs Human Research: Endpoint Comparison
IENFD (nerve fiber density) +60–78% restoration in diabetic neuropathy models (8–12 weeks) +10–20% improvement in T2D polyneuropathy (12 weeks); responder rate 28–35% Partial. Mechanism confirmed but magnitude reduced Translates mechanistically but requires hi
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- IENFD (nerve fiber density)
- +60–78% restoration in diabetic neuropathy models (8–12 weeks)
- +10–20% improvement in T2D polyneuropathy (12 weeks); responder rate 28–35%
- Partial. Mechanism confirmed but magnitude reduced
- Translates mechanistically but requires higher dose or longer duration than animal data suggest
- Neuropathic pain (behavioral/subjective)
- 45–60% reduction in mechanical hyperalgesia (von Frey testing)
- 18–25% reduction in NPSI scores; 28% responder rate (≥30% pain reduction)
- Partial. Statistically significant but clinically modest
- Animal models overestimate magnitude; human baseline variability and placebo response limit effect size
- Infarct size (cardiac ischemia-reperfusion)
- 35–42% reduction in porcine MI models (72 hours post-reperfusion)
- No large-scale human MI trial published; case reports suggest 15–20% reduction in troponin release
- Insufficient data. Mechanism plausible but unvalidated
- Requires Phase 2/3 human trial with imaging endpoints; animal data provide proof-of-concept only
- Inflammatory markers (TNF-alpha, IL-6, CRP)
- 40–60% reduction in rodent sepsis and colitis models (24–48 hours)
- 20–35% reduction in sarcoidosis patients (28 days); inconsistent across autoimmune conditions
- Partial. Anti-inflammatory effect confirmed but context-dependent
- Human immune complexity introduces variability animal models don't capture; baseline cytokine profile predicts response
- Receptor expression (EPO-R, CD131)
- Uniform across inbred strains; minimal inter-animal variability
- 4–6 fold variability in human peripheral nerve and cardiac tissue biopsies
- No translation. Animal uniformity doesn't reflect human heterogeneity
- Baseline receptor screening essential for human protocol design; animal data cannot predict individual human response
- Adverse events
- None reported at doses up to 100 mcg/kg in rodents or primates
- Mild injection site reactions (15–20%); no serious AEs in trials up to 8 mg three times weekly
- Translates well. Safety profile consistent
- ARA-290 safety translates robustly; the challenge is efficacy magnitude, not tolerability